Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 3:21 PM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 4,251 matching trials from the local directory fallback.

Filters: Intervention: placebo Clear all

Conditions: Diabetes, Kidney Disease, Retinopathy, Vascular Disease
Interventions: Montelukast, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes (T1D)
Interventions: Golimumab, Placebo (matching golimumab); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 2 Years to 44 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alcohol Use Disorder
Interventions: Nimodipine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Obesity/Therapy
Interventions: Placebo, Semaglutide 1.7mg subcutaneous; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 12 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Menopause, Sleep Quality
Interventions: Lotus Seed & Rice Germ Extract, Placebo; Dietary Supplement · Other
Lead sponsor: Nutraland USA, Inc.; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Adult Participants, Healthy Aging, Systemic Inflammation (hsCRP), Vitality
Interventions: Apple Extract, Placebo; Dietary Supplement · Other
Lead sponsor: Nutraland USA, Inc.; Industry
Eligibility: 45 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Post Operative Pain, Acute
Interventions: Acetaminophen 500mg, Combogesic® tablets, Placebo; Drug
Lead sponsor: AFT Pharmaceuticals, Ltd.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Crohn's Disease
Interventions: H021 Enteric-coated Tablets High-dose Group, H021 Enteric-coated Tablets Low-dose Group, Placebo Group; Drug
Lead sponsor: Jiangsu Carephar Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Hamden, Connecticut • Lighthouse PT, Florida • Orlando, Florida

Conditions: HIV Prevention
Interventions: Alhydrogel adjuvant, GLA-SE adjuvant, PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Placebo for DNA Vaccines, Protein Vaccines and Adjuvants; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
Interventions: AVTX-801, Placebo; Drug
Lead sponsor: Eva Morava-Kozicz; Other
Eligibility: 1 Month and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 1 Diabetes (T1D)
Interventions: Placebo, SAB-142; Drug
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 40 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 1 more

Conditions: Adderall, PTSD, Post Traumatic Stress Disorder
Interventions: Adderall, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Liver Fibrosis, Cirrhosis, Liver
Interventions: Placebo, erlotinib hydrochloride; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dehydration (Physiology), Hydration, Performance
Interventions: 6% Sports drink, Carbohydrate Milk Permeate sports drink, Low-Carbohydrate Milk Permeate sports drink, Water (Placebo); Dietary Supplement
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Long COVID
Interventions: Atorvastatin, 10mg, 20mg, 40mg, Maraviroc (MVC), Placebo, Atorvastatin, Placebo, Maraviroc; Drug
Lead sponsor: HealthBio, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy
Interventions: Essential Oil, Placebo supplement, essential oil supplement, placebo essential oil; Other · Dietary Supplement
Lead sponsor: dōTERRA International; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Pleasant Grove, Utah

Conditions: Cognitive Function, Fatigue, Global Mental Health, Sleep Disturbance
Interventions: Energy Active Product 1, Energy Product Placebo Control; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Depression, Knee Osteoarthritis, Pain
Interventions: Duloxetine, Exercise, PT referral, Placebo; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Placebo, Psilocybin 15mg; Drug
Lead sponsor: Manoj Doss; Other
Eligibility: 21 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Austin, Texas

Conditions: PONV
Interventions: Aprepitant Injection, Dexamethasone, Ondansetron (Zofran), Placebo; Drug · Other
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Skokie, Illinois

Conditions: Osteoarthitis
Interventions: Cannabidiol (CBD), Castor Oil (Placebo); Dietary Supplement · Other
Lead sponsor: University of Tennessee; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Opioid Use Disorder
Interventions: Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution, Placebo Dronabinol, Placebo Epidiolex; Drug · Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Bannayan Riley Ruvalcaba Syndrome, Bannayan Zonana Syndrome, Cerebellum Dysplastic Gangliocytoma, Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Myhre Riley Smith Syndrome, PTEN Hamartoma Tumor Syndrome, Riley Smith Syndrome
Interventions: Everolimus blinded oral capsules, Placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 5 Years to 45 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Stanford, California • Boston, Massachusetts • Cleveland, Ohio

Conditions: Acute Ischemic Stroke
Interventions: Intravenous tenecteplase (TNK), Placebo; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Neptune City, New Jersey

Search by objective public record fields.

MIRACLE-T2D Montelukast Intervention for Renal, Cardiovascular and Eye Health in Type 2 Diabetes

Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

Effects of Nimodipine on Alcohol Drinking

Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity

Effect of ZenRest™ Lotus Seed & Rice Germ Extract Blend on Sleep Quality in Menopausal Women

Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects

A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery

A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

AVTX-801 D-galactose Supplementation in SLC35A2-CDG

PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

Effects of Stimulant Medications in PTSD

Erlotinib for Hepatocellular Carcinoma Chemoprevention

The Role of Carbohydrate Blends and Electrolytes on Physical and Mental Performance During Cycling in the Heat

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

Essential Oil-Based Product System for Digestive Support

Radicle Energy VBMTM: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes

Duloxetine and aeRobic Exercise to Improve Function in VEterans With Knee Osteoarthritis (DRIVE)

The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function

Aprepitant to Improve Same Day Discharge for TKA

CBD Knee Osteoarthritis Study

Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Efficacy and Safety of Tenecteplase Among acutE Ischemic Stroke Patients With Recent Ingestion of Direct Oral Anticoagulant